#United States #Mountain View #Turn Biotechnologies #ARMMs Technology #Epigenetic Therapy

Turn Biotechnologies Makes a Bold Move with ARMMs Acquisition

Turn Biotechnologies recently announced its acquisition of the innovative ARMMs (ARRDC1 Mediated Microvesicles) technology, establishing a new frontier in its epigenetic reprogramming therapies. This strategic move promises to greatly enhance the ability of the company to target various tissues, cells, and organs with previously unattainable precision.

The Power of ARMMs

The newly integrated ARMMs technology focuses on delivering gene editors, proteins, and RNA-based therapies through a non-viral vesicular delivery system. This breakthrough allows for an expansive range of therapeutic possibilities, targeting conditions in ophthalmology, dermatology, and immune therapies. The combination of ARMMs with Turn Biotechnologies' existing eTurna™ LNP (lipid nanoparticle) platforms is expected to revolutionize the delivery mechanisms of epigenetic treatments. Anja Krammer, CEO of Turn Biotechnologies, emphasized the significance of this acquisition, noting its potential for exact and scalable treatment regimens.

Enhancing Delivery Capabilities

The incorporation of ARMMs means that Turn Biotechnologies can now safely deliver larger and more diverse therapeutic payloads. This increased delivery capability encompasses not only gene and epigenetic editors but also other vital cargo forms, which previously faced challenges in efficient delivery. Moreover, the ARMMs technology has shown promising preclinical data, effectively delivering therapies across various tissues, including the retinal, lung, nervous system, liver, and spleen, showcasing its vast therapeutic potential.

Implications for Epigenetic Reprogramming

Turn Biotechnologies' mission is focused on utilizing epigenetics to restore a youthful and functional cellular state, treating conditions linked to aging. By enabling modulation of gene expression, this technology opens doors to combat age-related diseases such as skin aging, muscle degeneration, joint issues, and vision loss. This acquisition is likely to accelerate the development of Turn Biotechnologies' drug candidates aimed at rejuvenating immune cells and revitalizing skin health, solidifying their position in the epigenetics space.

The Road Ahead

As Turn Biotechnologies progresses with its revamped pipeline post-acquisition, investor interest has surged. Notable investors, including Bayer Healthcare LLC and Alexandria Ventures, have taken a keen interest in the company's trajectory. The anticipation surrounding the advancements enabled by the ARMMs technology is high. As the company shifts its focus toward deploying these groundbreaking therapies, clients and patients alike eagerly await tangible outcomes from this innovative leap.

In conclusion, the acquisition of ARMMs technology represents an important milestone for Turn Biotechnologies in its quest to advance the field of regenerative medicine. With its emphasis on precision medicine and enhancing therapy accessibility, the company stands on the brink of transformative developments in healthcare aimed at tackling the challenges associated with aging.

For more information about Turn Biotechnologies and its path forward, visit the company’s official website.